Northwest Biotherapeutics (NWBO) EBIAT (2016 - 2025)
Northwest Biotherapeutics (NWBO) has 16 years of EBIAT data on record, last reported at -$26.8 million in Q3 2025.
- For Q3 2025, EBIAT fell 38.48% year-over-year to -$26.8 million; the TTM value through Sep 2025 reached -$89.8 million, down 20.54%, while the annual FY2024 figure was -$83.8 million, 33.83% down from the prior year.
- EBIAT reached -$26.8 million in Q3 2025 per NWBO's latest filing, down from -$15.4 million in the prior quarter.
- Across five years, EBIAT topped out at $4.4 million in Q2 2021 and bottomed at -$32.9 million in Q3 2022.
- Average EBIAT over 5 years is -$18.4 million, with a median of -$18.6 million recorded in 2023.
- Peak YoY movement for EBIAT: skyrocketed 107.6% in 2021, then plummeted 772.74% in 2022.
- A 5-year view of EBIAT shows it stood at $4.4 million in 2021, then tumbled by 742.45% to -$28.3 million in 2022, then surged by 33.22% to -$18.9 million in 2023, then tumbled by 49.18% to -$28.2 million in 2024, then rose by 4.94% to -$26.8 million in 2025.
- Per Business Quant database, its latest 3 readings for EBIAT were -$26.8 million in Q3 2025, -$15.4 million in Q2 2025, and -$19.3 million in Q1 2025.